Double-blind, vehicle-controlled clinical investigation of peptide OS-01 for skin rejuvenation

OS-01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation Markers: A Pilot 12-Week Clinical Trial

OBJECTIVE

As the body's largest organ, the skin plays a crucial role in defending against external stressors. Skin characteristics change with age, decreasing skin barrier integrity and compromising skin and body health. This study aimed to investigate the potential of a topical formulation containing OS-01 (a.k.a. Peptide 14), a senotherapeutic peptide, to counteract age-related skin changes and their systemic consequences.

METHODS

A randomized, double-blinded clinical trial involving 60 female volunteers aged 60-90 was conducted over 12 weeks. Participants received either an OS-01 topical formulation or a commercially available moisturizer control formulation. Skin parameters, subjective perceptions, and circulating cytokine levels were assessed. Skin instrumental analysis included transepidermal water loss (TEWL), skin hydration, and pH measurements.

RESULTS

Participants treated with the OS-01 topical formulation displayed significantly improved skin barrier function and hydration compared to the control group. Participant perceptions aligned with objective findings: after 12 weeks, 70% of participants in the OS-01 group noticed an improvement in general skin appearance versus 42% for the control group. The systemic levels of proinflammatory cytokines tended to normalize, with a significant decrease in IL-8 in the blood analysis of participants from the OS-01 group. On the other hand, the control group demonstrated an increase in a few circulating cytokines, particularly TNF-ɑ and IFN-γ. Moreover, GlycanAge analysis measuring participants' biological age suggested the slowing of systemic aging in the group treated with the OS-01 topical formulation.

CONCLUSION

The study suggests that the OS-01 formulation can impact skin health by improving the skin barrier function, potentially influencing systemic inflammation and biological age. In conclusion, the study supports that targeting skin health may contribute to better longevity outcomes, underscoring the skin's pivotal role in systemic aging and supporting an integrated approach to health management.

Clinical efficacy of OS-01 peptide formulation in reducing the signs of periorbital skin aging

BACKGROUND

The aging of the skin, particularly around the periorbital region, is a complex process characterized by the accumulation of senescent cells, decreased collagen production, and reduced skin elasticity, leading to visible signs such as fine lines, wrinkles, and sagging.

OBJECTIVE

This study investigates the efficacy of a novel topical formulation, OS-01 EYE, containing the senomorphic peptide, OS-01, along with other active ingredients, in improving the skin around the eyes.

METHODS

A 12-week clinical study was conducted with 22 participants who applied OS-01 EYE twice daily. Assessments included bioinstrumental measurements of skin hydration, barrier function, firmness, and elasticity, as well as expert photographs grading fine lines, wrinkles, under-eye puffiness, and dark circles.

RESULTS

After 12 weeks of product use, transepidermal water loss (TEWL) decreased by 17.33%, hydration increased by 32.49%, skin firmness improved by 10.19%, and elasticity increased by 25.58%, compared to baseline, which was all statistically significant. Expert grading revealed a decrease in fine lines and wrinkles, under-eye puffiness, and dark circles over the study period. Furthermore, subjective assessments showed that 95.46% of participants reported improvements in overall appearance.

CONCLUSION

The OS-01 EYE formulation was found to be safe and effective in mitigating the visible signs of aging in the periorbital region, making it a potent treatment option for enhancing periorbital skin health, function, and appearance.